Ardelyx, Inc. (ARDX) stock
Close on Nov 12, 2026Market cap $777.47MP/E –Yield –
Ardelyx, Inc. grew revenue 16.8% to $450.89M over the twelve months to Jun 30, 2026. Free cash flow was -$17.92M. At the latest close the market valued the company at $777.47M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $777.47M
- P/E ratio
- –
- Price to sales
- 1.72
- Price to book
- 5.22
- Dividend yield
- –
- Free cash flow yield
- -2.30%
Fundamentals
- Revenue
- $450.89M
- Net income
- -$55.70M
- EPS, diluted
- -$0.22
- Free cash flow
- -$17.92M
- Book value per share
- $0.60
- Diluted shares
- 248M
Trading
- Next earnings
- Feb 18, 2027 (estimated, during market hours)
- Previous close
- $3.13
- Open
- $3.15
- Day's range
- $3.01 – $3.17
- Volume
- 4,034,894
- Average volume (20 days)
- 4,883,671
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 0.95
- 52-week range
- $2.80 – $8.40
- RSI (14 days)
- 48.7
- Volatility (1 year)
- 58.2%
- Relative volume
- 0.93×
- WACC
- 9.8%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ARDX | S&P 500 | Difference | ARDX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.4% | -2.7% | −0.7 pts | ||
| 3 months | -21.4% | -1.7% | −19.7 pts | ||
| Year to date | -46.5% | +11.9% | −58.4 pts | ||
| 1 year | -48.3% | +12.0% | −60.3 pts | ||
| 3 years | -12.4% | +78.2% | −90.5 pts | -4.3% | +21.2% |
| 5 years | +178.6% | +73.2% | +105.3 pts | +22.7% | +11.6% |
| 10 years | -80.4% | +309.6% | −390.1 pts | -15.1% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ardelyx filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Ardelyx
Pharmaceutical Preparations
Ardelyx is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes small molecule therapies for unmet medical needs. It markets two products based on the active ingredient tenapanor: IBSRELA, which treats adults with irritable bowel syndrome with constipation, and XPHOZAH, which reduces serum phosphorus in adults with chronic kidney disease on dialysis. The company also develops pipeline candidates, including next-generation NHE3 inhibitors. Its end customers are adult gastrointestinal and kidney disease patients, reached through healthcare prescribers and commercial partners.
Company profile, executives and historyArdelyx stock: common questions
What is Ardelyx's stock price?
ARDX closed at $3.12 on Nov 12, 2026, down 0.32% on the day. Over the past 52 weeks it traded between $2.80 and $8.40.
What is Ardelyx's market cap?
Ardelyx was worth $777.47M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ARDX's P/E ratio?
Ardelyx lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.22), so it has no meaningful P/E ratio.
How much revenue does Ardelyx make?
Ardelyx reported revenue of $450.89M for the twelve months to Jun 30, 2026, up 16.8% from a year earlier.
Does Ardelyx pay a dividend?
No. Ardelyx has not paid a cash dividend over the last twelve months.
When does Ardelyx report earnings next?
Ardelyx is expected to report Q4 FY2026 results on Feb 18, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ARDX stock performed over the past year?
Including dividends, ARDX returned -48.3% over the past year, against +12.0% for the S&P 500.
How many ARDX shares are sold short?
29M shares were sold short at the latest FINRA report, 12.59% of the float, or 7.5 days of average trading volume.
Who are Ardelyx's competitors?
Companies most similar to Ardelyx by business, industry and size include IRWD, AKBA, XERS, MIRM, TVTX.
See a number that looks wrong?